Real-time Estimate
Cboe BZX
12:14:20 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
4.265
USD
|
+2.77%
|
|
-2.56%
|
+132.22%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
353.3
|
46.7
|
79.75
|
244.3
|
-
|
-
|
Enterprise Value (EV)
1 |
78.6
|
-134.1
|
79.75
|
244.3
|
244.3
|
244.3
|
P/E ratio
|
-4.74
x
|
-0.37
x
|
-0.97
x
|
-4.38
x
|
-2.9
x
|
-3.13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
19
x
|
-
|
39.1
x
|
EV / Revenue
|
-
|
-
|
-
|
19
x
|
-
|
39.1
x
|
EV / EBITDA
|
-5,115,596
x
|
-380,378
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-9,851,510
x
|
-487,808
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
1.38
x
|
0.29
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
32,209
|
34,851
|
44,304
|
58,876
|
-
|
-
|
Reference price
2 |
10.97
|
1.340
|
1.800
|
4.150
|
4.150
|
4.150
|
Announcement Date
|
3/29/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
12.89
|
-
|
6.25
|
EBITDA
|
-
|
-69.07
|
-122.8
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-69.72
|
-123.5
|
-82.2
|
-69.58
|
-90.99
|
-117
|
Operating Margin
|
-
|
-
|
-
|
-
|
-539.86%
|
-
|
-1,872.19%
|
Earnings before Tax (EBT)
1 |
-
|
-75.98
|
-120.7
|
-73.79
|
-59.3
|
-87.27
|
-113.5
|
Net income
1 |
-12.83
|
-75.98
|
-120.7
|
-73.79
|
-59.3
|
-87.27
|
-113.5
|
Net margin
|
-
|
-
|
-
|
-
|
-460.16%
|
-
|
-1,816.17%
|
EPS
2 |
-1.960
|
-2.313
|
-3.650
|
-1.850
|
-0.9467
|
-1.433
|
-1.325
|
Free Cash Flow
|
-
|
-35.87
|
-95.73
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/21/21
|
3/29/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
16.15
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-16.27
|
-31.23
|
-25.57
|
-28.19
|
-37.78
|
-
|
-17.6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.43
|
-31.39
|
-25.73
|
-28.39
|
-37.97
|
-20.95
|
-18.12
|
-25.35
|
-17.77
|
-5.605
|
-20.37
|
-20.27
|
-20.41
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-34.71%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-16.83
|
-31.38
|
-25.56
|
-27.67
|
-36.1
|
-19.24
|
-15.9
|
-23.05
|
-15.6
|
-3.256
|
-18.35
|
-16.77
|
-17.33
|
-
|
-
|
Net income
1 |
-16.83
|
-31.38
|
-25.56
|
-27.67
|
-36.1
|
-19.24
|
-15.9
|
-23.05
|
-15.6
|
-3.256
|
-18.35
|
-16.77
|
-17.33
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-20.17%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5700
|
-0.9700
|
-0.7900
|
-0.8500
|
-1.040
|
-0.5400
|
-0.4100
|
-0.5600
|
-0.3300
|
-0.0600
|
-0.3133
|
-0.2767
|
-0.2833
|
-0.3850
|
-0.3650
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
5/13/22
|
8/15/22
|
11/1/22
|
3/22/23
|
5/11/23
|
8/11/23
|
11/7/23
|
3/21/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
275
|
181
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-35.9
|
-95.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-61.9%
|
-57.2%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
7.970
|
4.600
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-4.160
|
-2.700
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.54
|
-
|
6.73
|
4.26
|
3.48
|
7.09
|
Capex / Sales
|
-
|
-
|
-
|
-
|
33.05%
|
-
|
113.36%
|
Announcement Date
|
6/21/21
|
3/29/22
|
3/22/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
4.15
USD Average target price
8.8
USD Spread / Average Target +112.05% Consensus |
1st Jan change
|
Capi.
|
---|
| +132.22% | 244M | | +9.85% | 115B | | +11.79% | 106B | | -2.59% | 21.96B | | -13.45% | 21.87B | | -5.29% | 19.21B | | -2.92% | 18.08B | | -38.57% | 17.71B | | +6.23% | 14.32B | | +34.10% | 12.42B |
Bio Therapeutic Drugs
|